• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva touts first implant of Fantom Encore bioresorbable scaffold in Switzerland

March 28, 2018 By Sarah Faulkner

Reva MedicalReva Medical (ASX:RVA) announced today that the company’s Fantom Encore bioresorbable vascular scaffold was used for the first time in Switzerland.

The sirolimus-eluting device, which is made from Reva’s proprietary Tyrocore polymer, features a 95-micron strut profile and x-ray visibility.

“Reva’s Tyrocore polymer makes Fantom Encore the most advanced bioresorbable scaffold with x-ray visibility and the thinnest strut profile in the 2.5 mm diameter size,” Dr. Gregor Leibundgut, who conducted the procedure, said in prepared remarks. “During the procedure, I experienced the flexibility and ease-of-use provided by a thinner strut profile as well as excellent scaffolding. A thinner strut profile, without compromising strength, as well as the excellent visibility of the scaffold are some of the most important improvements over first generation bioresorbable scaffolds.”

The company launched its commercial operations in Switzerland last year and has since won CE Mark approval in the European Union for its Fantom Encore device.

Bioresorbable scaffolds, designed to improve upon metal drug-eluting stents, have suffered in reputation thanks to concerns about an increased risk of myocardial infarction and scaffold thrombosis linked with the devices.

But Reva has argued that first-gen bioresorbable scaffolds were limited due to their thick strut profiles. Thinner profiles, like the ones sported by Fantom and Fantom Encore, help promote long-term clinical success, according to the company.

“Many of the physicians we work with believe that bioresorbable scaffolds are the future of coronary artery disease therapy. With its thin strut profile, x-ray visibility, and ease-of-use, Fantom Encore is delivering that future today,” CEO Reggie Groves added. “The first implant of Fantom Encore in Switzerland is an important step in expanding use of our technology and broader commercial adoption.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Wall Street Beat Tagged With: Reva Medical

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS